Sino Biopharmaceutical Management
Management criteria checks 1/4
Sino Biopharmaceutical's CEO is Eric S. Y. Tse, appointed in Jul 2022, has a tenure of 4.75 years. total yearly compensation is CN¥49.69M, comprised of 45.4% salary and 54.6% bonuses, including company stock and options. directly owns 22.11% of the company’s shares, worth HK$10.83B. The average tenure of the management team and the board of directors is 1.5 years and 9.2 years respectively.
Key information
Eric S. Y. Tse
Chief executive officer
CN¥49.7m
Total compensation
| CEO salary percentage | 45.4% |
| CEO tenure | 2yrs |
| CEO ownership | 22.1% |
| Management average tenure | 1.5yrs |
| Board average tenure | 9.2yrs |
Recent management updates
Recent updates
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued
Jan 22Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet
Dec 03Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Oct 19Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02
Sep 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | CN¥50m | CN¥23m | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥2b |
| Mar 31 2023 | n/a | n/a | CN¥2b |
| Dec 31 2022 | n/a | n/a | CN¥2b |
| Sep 30 2022 | n/a | n/a | CN¥5b |
| Jun 30 2022 | n/a | n/a | CN¥8b |
| Mar 31 2022 | n/a | n/a | CN¥14b |
| Dec 31 2021 | CN¥23m | CN¥6m | CN¥15b |
| Sep 30 2021 | n/a | n/a | CN¥12b |
| Jun 30 2021 | n/a | n/a | CN¥10b |
| Mar 31 2021 | n/a | n/a | CN¥4b |
| Dec 31 2020 | CN¥25m | CN¥7m | CN¥3b |
| Sep 30 2020 | n/a | n/a | CN¥2b |
| Jun 30 2020 | n/a | n/a | CN¥3b |
| Mar 31 2020 | n/a | n/a | CN¥3b |
| Dec 31 2019 | CN¥6m | CN¥870k | CN¥3b |
Compensation vs Market: Eric S. Y.'s total compensation ($USD6.83M) is above average for companies of similar size in the Hong Kong market ($USD889.94K).
Compensation vs Earnings: Eric S. Y.'s compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Eric S. Y. Tse (28 yo)
2yrs
Tenure
CN¥49,691,000
Compensation
Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairwoman of the Board | 9.1yrs | CN¥49.69m | 0.033% CN¥ 16.0m | |
| CEO & Executive Director | 2yrs | CN¥49.69m | 22.11% CN¥ 10.8b | |
| Founder & Senior Executive Vice Chairman | 3.9yrs | CN¥49.53m | 9.12% CN¥ 4.5b | |
| Executive Vice Chairwoman of the Board | 7.3yrs | CN¥43.13m | 16.19% CN¥ 7.9b | |
| Executive Director | no data | CN¥1.91m | no data | |
| Senior VP & Executive Director | no data | CN¥6.41m | 1.95% CN¥ 954.7m | |
| Chief Financial Officer | 1.5yrs | no data | no data | |
| Vice President of Public Affairs | no data | no data | no data | |
| Chief Strategy Officer | 1.5yrs | no data | no data | |
| Chief Scientific Advisor of invoX | 1.5yrs | no data | no data | |
| Assistant VP & Financial Controller | no data | no data | no data | |
| Company Secretary | 8.9yrs | no data | no data |
1.5yrs
Average Tenure
54yo
Average Age
Experienced Management: 1177's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairwoman of the Board | 9.1yrs | CN¥49.69m | 0.033% CN¥ 16.0m | |
| CEO & Executive Director | 4.8yrs | CN¥49.69m | 22.11% CN¥ 10.8b | |
| Founder & Senior Executive Vice Chairman | 3.9yrs | CN¥49.53m | 9.12% CN¥ 4.5b | |
| Executive Vice Chairwoman of the Board | 7.3yrs | CN¥43.13m | 16.19% CN¥ 7.9b | |
| Executive Director | 9.3yrs | CN¥1.91m | no data | |
| Senior VP & Executive Director | no data | CN¥6.41m | 1.95% CN¥ 954.7m | |
| Independent Non-Executive Director | 18.7yrs | CN¥376.00k | no data | |
| Independent Non-Executive Director | 19.8yrs | CN¥376.00k | no data | |
| Independent Non-Executive Director | 9.3yrs | CN¥376.00k | no data | |
| Independent Non-Executive Director | 9.3yrs | CN¥342.00k | no data | |
| Independent Non-Executive Director | 3.6yrs | CN¥376.00k | 0.00039% CN¥ 190.9k |
9.2yrs
Average Tenure
60yo
Average Age
Experienced Board: 1177's board of directors are considered experienced (9.2 years average tenure).